A collaboration involving Trenchant BioSystems, the University of Massachusetts Chan Medical School, and Caring Cross aims to develop a scalable hematopoietic stem cell (HSC) manufacturing platform suitable for place-of-care settings. The partners plan to use Trenchant’s AutoCell automated CGT manufacturing approach and a microbubble separation method intended to replace immunomagnetic bead workflows. The alliance’s early work will evaluate blood products for stem cell separation and build a gene-transfer platform with lentiviral vectors from Caring Cross. The stated pathway includes preclinical studies followed by a planned Phase I/II trial for autologous gene-modified HSCs in sickle cell disease or beta thalassemia. The operational emphasis on ISO class 7 environments and reduced facility requirements reflects a practical manufacturing bottleneck that has limited access to CGTs—making regulatory interaction and trial readiness a close watch item.